Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Solid Biosciences (NASDAQ: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced the granting of 81,000 restricted stock units (RSUs) to seven newly hired employees. The RSUs will vest over a four-year period, with 25% vesting annually on each grant date anniversary. The equity awards were granted under the Company's 2024 Inducement Stock Incentive Plan and are contingent upon continued employment through each vesting date. These grants were made as inducement material for employment in accordance with Nasdaq Listing Rule 5635(c)(4).

CHARLESTOWN, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 81,000 restricted stock units (“RSUs”) to seven newly hired employees.

The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date.

This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.

Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com

Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com

FAQ

How many RSUs did Solid Biosciences (SLDB) grant to new employees in May 2025?

Solid Biosciences granted 81,000 restricted stock units (RSUs) to seven newly hired employees.

What is the vesting schedule for SLDB's May 2025 RSU grants?

The RSUs vest in four equal installments, with 25% vesting on each anniversary of the grant date over four years.

Under which plan were Solid Biosciences' May 2025 RSU grants made?

The grants were made under Solid Biosciences' 2024 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

What type of medicines is Solid Biosciences (SLDB) developing?

Solid Biosciences is developing precision genetic medicines for neuromuscular and cardiac diseases.